Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Supha Pharmachem Ltd (539561)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539561 NSE: Trading | Small Cap | Supha Pharmachem Share Price
₹0.26 -0.01 (-3.70%)
As on 23-Sep'26 15:32
Supha Pharmachem Ltd (539561)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539561 NSE: Trading | Small Cap | Supha Pharmachem Share Price
₹0.26 -0.01 (-3.70%)
As on 23-Sep'26 15:32
Key Metrics
Valuation Multiples
Market Cap
₹24 Cr.
Current Price
₹0.3
52-Week Low / High
₹0 / 2
TTM EPS
₹0
TTM Sales
₹405 Cr.
Book Value per Share
₹1.2
P/E Ratio
11.18
Lower than its 5-year historical median
Industry PE
39.8
Price to Book (P/B)
0.23
Lower than its 5-year historical median
Price to Sales (P/S)
0.06
Lower than its 5-year historical median
EV/EBITDA
92.02
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
4.85%
Underperforms industry median
Return on Capital Employed (ROCE)
1.01%
Underperforms industry median
Return on Assets (ROA)
0.12%
Operating Profit Margin
0.3%
Net Profit Margin
0.53%
Gross Profit Margin
1.1%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-94.49%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
1.13%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹17 Cr.
Equity
₹88.2 Cr.
Face Value
₹1
All Time Low / High
₹0.07 / 31.35
Check Before You Invest
M-Cap below 100cr DeciZen not available
Is Supha Pharmachem Ltd a good quality company?
Supha Pharmachem Ltd is a quality company, based on a multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Supha Pharmachem Ltd performance compare with that of its Peers?
Revenue growth of Supha Pharmachem Ltd vs industry peers?
Supha Pharmachem Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Supha Pharmachem Ltd?
Promoters hold 1.13% of the Supha Pharmachem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Supha Pharmachem Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of -19.31% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Supha Pharmachem Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0.7% | 0.1% | 0.6% | 0.6% | 11.2% | 7.4% | 18.2% | 102.5% | 99.5% | 1.8% | - |
| Value Creation Index ⓘ | -1.0 | -1.0 | -1.0 | -1.0 | -0.2 | -0.5 | 0.3 | 6.3 | 6.1 | -0.9 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 3.9 | 1.3 | 0.4 | 0.2 | 2.9 | 90 | 505 | 510 | 4,042 | 223 | 147 |
| Sales YoY Gr. | - | -66.2% | -73.7% | -54.3% | 1,706.3% | 3,015.2% | 460.7% | 1% | 692.7% | -94.5% | - |
| Adj EPS ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0.3 | -0.1 | -0 |
| YoY Gr. | - | NA | NA | NA | NA | NA | 100% | 300% | 287.5% | -132.3% | - |
| BVPS (₹) ⓘ | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.7 | 0.8 | 1 |
| Adj Net Profit ⓘ | 0 | 0 | 0 | 0 | 0.3 | 0.5 | 1.1 | 4.9 | 18 | -5.9 | -2 |
| Cash Flow from Ops. ⓘ | -1.4 | 0.1 | -0.2 | -0.1 | -0.2 | -10.2 | 11.3 | 20.5 | -74.2 | -1,079 | - |
| Debt/CF from Ops. ⓘ | -0 | 0 | 0 | -1.1 | -1.8 | -1 | 0 | 0 | -0.8 | -1.1 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 56.6% | 138.4% | -23.9% | -94.5% | ||||
| Adj EPS ⓘ | NA | NA | -271% | -132.3% | ||||
| BVPSⓘ | 35.1% | 65.7% | 102.7% | 1.4% | ||||
| Share Price | - | -19.3% | -77.2% | -82.7% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0.3 | 0.1 | 0.5 | 0.2 | 8.4 | 13.3 | 24.5 | 63.4 | 67.7 | -13.8 | -2.3 |
| Op. Profit Mgn % ⓘ | -7.6 | -7.4 | 0.2 | -43.2 | 13.4 | 0.8 | 0.4 | 1.4 | 0.9 | 0.2 | -9.4 |
| Net Profit Mgn % ⓘ | 0.2 | 0.3 | 3.9 | 3.9 | 9.4 | 0.5 | 0.2 | 1 | 0.5 | -2.7 | -1.2 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0.1 | 2.7 | 0 | 0 | 1.3 | 26.4 | 12 |
| Working Cap Days ⓘ | 415 | 1,050 | 3,243 | 6,366 | 351 | 82 | 94 | 485 | 139 | 2,858 | 4,398 |
| Cash Conv. Cycle ⓘ | 325 | 801 | 2,189 | 2,045 | 110 | 10 | 17 | 27 | 21 | 1,038 | 3,071 |
Valuation of Supha Pharmachem - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'25 |
|---|---|
| Sales | 405.25 |
| Operating Expenses ⓘ + | 403.99 |
| Operating Profit ⓘ | 1.26 |
| Operating Profit Margin (%) | 0.3% |
| Other Income ⓘ + | 10.80 |
| Interest ⓘ | 7.64 |
| Depreciation ⓘ | 0.04 |
| Profit Before Tax ⓘ | 4.38 |
| Tax ⓘ | 2.26 |
| Profit After Tax | 2.13 |
| PAT Margin (%) | 0.5% |
| Adjusted EPS (₹) | 0.0 |
| Dividend Payout Ratio (%) | 0% |
| PARTICULARS | Mar'25 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 43.89 | ||||||||||
| Debt + | 1,141.39 | ||||||||||
| Minority Interest | 0 | ||||||||||
| Trade Payables | 500.96 | ||||||||||
| Others Liabilities ⓘ | 34.07 | ||||||||||
| Total Liabilities ⓘ | 1,720.31 | ||||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 0.01 | ||||||||||
| CWIP ⓘ | 0 | ||||||||||
| Investments ⓘ | 0 | ||||||||||
| Inventories | 269.38 | ||||||||||
| Trade Receivables | 771.62 | ||||||||||
| Cash Equivalents | 1.43 | ||||||||||
| Others Assets ⓘ | 677.88 | ||||||||||
| Total Assets ⓘ | 1,720.31 | ||||||||||
| PARTICULARS | Mar'25 |
|---|---|
| Cash Flow From Operating Activity ⓘ + | -1,134.81 |
| Cash Flow From Investing Activity ⓘ + | 0.13 |
| Cash Flow From Financing Activity ⓘ + | 1,136.10 |
| Net Cash Flow ⓘ | 1.43 |
| PARTICULARS | Mar'25 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 4.85 | |||||||||
| ROCE (%) | 1.01 | |||||||||
| Asset Turnover Ratio | 0.24 | |||||||||
| PAT to CFO Conversion(x) | -532.77 | |||||||||
| Working Capital Days | ||||||||||
| Receivable Days | 695 | |||||||||
| Inventory Days | 242.60 | |||||||||
| Payable Days | 459.30 | |||||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Supha Pharmachem Ltd FAQs
The current trading price of Supha Pharmachem on 23-Sep-2026 15:32 is ₹0.26.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2026 the market cap of Supha Pharmachem stood at ₹23.81 Cr
The latest P/E ratio of Supha Pharmachem as of 22-Sep-2026 is 0.00.
The latest P/B ratio of Supha Pharmachem as of 22-Sep-2026 is 0.26.
The 52-week high of Supha Pharmachem is ₹1.80 and the 52-week low is ₹0.25.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Supha Pharmachem is ₹147 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Supha Pharmachem Ltd is a below average quality company.
The key valuation ratios of Supha Pharmachem Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Supha Pharmachem Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Supha Pharmachem Ltd
Remedium Lifecare Ltd. (formerly known as Roxy Exports Limited) is a BSE listed company. The company has made a paradigm shift by entering into the manufacturing of intermediates and APIs and be reckoned as a leading contract manufacturer and as a brand owner of advanced intermediates & APIs. The strategic acquisition of the state-of-the-art manufacturing facilities in Hyderabad, was a timely move to forward integrate and diversify into the pharma & healthcare arena. A massive facility with 2 dedicated manufacturing blocks is now ready for large scale manufacture.
The company is engaged into the business of trading in API Intermediates (KSMs & CRMs) and various other raw materials used in API trading viz. Amino isophthalic Acid, Tellurium (IV) Oxide, Grignard Reagent, lodine, Selenium Metal Powder, Trimethyl Sulfoxonium lodide (TMSI).
Business area of the company
The company is pharmaceutical company aligned across two business verticals viz. Products and Services. Its Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both Domestic and International markets including the regulated markets.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
